Login / Signup

Heart Failure with Preserved Ejection Fraction-a Concise Review.

Daria M KellerMary-Tiffany OduahThomas KiebaloSonia NartowiczMarcin BębenMateusz PochylskiAleksandra CiepłuchaAdrian GwizdałaMaciej LesiakEwa Straburzyńska-Migaj
Published in: Current cardiology reports (2020)
It has recently been proposed that heart failure (HF) is rather a heterogeneous syndrome with a spectrum of overlapping and distinct characteristics. HFpEF itself can be distilled into different phenotypes based on the underlying biology. The etiological factors of HFpEF are unclear; however, systemic low-grade inflammation and microvascular damage as a consequence of comorbidities associated with endothelial dysfunction, oxidative stress, myocardial remodeling, and fibrosis are considered to play a crucial role in the pathogenesis of a disease. The H2FPEF score and the HFpEF nomogram are recently validated highly sensitive tools employed for risk assessment of subclinical heart failure. Despite numerous studies, there is still no evidence-based pharmacotherapy for HFpEF and the mortality and morbidity associated with HFpEF remain high. A better understanding of the etiological factors, the impact of comorbidities, the phenotypes of the disease, and implementation of machine learning algorithms may play a key role in the development of future therapeutic strategies.
Keyphrases